Why the study?
Does outpatient management with rivaroxaban reduce the number of hospitalization days from venous thromboembolism and bleeding in low-risk pulmonary embolism patients compared to standard care?
Does outpatient management with rivaroxaban reduce the number of hospitalization days from venous thromboembolism and bleeding in low-risk pulmonary embolism patients compared to standard care?
The MERCURY PE study will evaluate whether early discharge and outpatient management with rivaroxaban reduces hospitalization days for low-risk pulmonary embolism patients.
Answers are grounded in this paper and cite their sources.
Will test early discharge with rivaroxaban in low-risk PE; extends observational data with randomized evidence.
The MERCURY PE study is designed to test the hypothesis that outpatient management of low-risk PE patients with rivaroxaban reduces the number of hospitalization days from venous thromboembolism and bleeding compared with standard care. This article describes the rationale and methodology for this study.
No takes yet. Share an insight, caveat, or question.
Singer et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: